Introduction

Precision oncology began gaining traction in the late 1990s and has since reshaped how we understand and treat cancer. Rather than classifying tumors solely by where they arise in the body, precision oncology asks a more fundamental question: What molecular alteration is driving this cancer? Our previous blog post: https://qualisuredx.com/precision-oncology-explained/ explored what precision oncology is and why it matters. In this article, we focus on the early breakthroughs that proved this approach could fundamentally change patient outcomes and redefined the research and development of cancer therapies.

Chronic Myeloid Leukemia and the BCR-ABL Fusion Gene

Chronic Myeloid Leukemia, or CML, is a blood cancer driven by a specific genetic alteration in which chromosomes 9 and 22 exchange segments, creating an abnormal fusion gene known as BCR ABL. This fusion gene encodes a tyrosine kinase protein that is permanently activated, essentially stuck in the “ON” position, continuously signaling white blood cells to grow and divide uncontrollably.

In 2001, the FDA approved imatinib, a tyrosine kinase inhibitor, or TKI, designed to specifically block the abnormal BCR-ABL protein. By targeting this single molecular driver, imatinib effectively halted cancer cell proliferation. As a first-line oral therapy, it enabled many patients with CML to achieve long-term disease control and dramatically improved survival.

The CML story is a great example of targeted therapy in action, where a cancer is primarily dependent on one dominant protein.

HER2-Positive Breast Cancer and Defining Molecular Subtypes

HER2-positive breast cancer is an aggressive molecular subtype of breast cancer. HER2 stands for human epidermal growth factor receptor 2. When there are too many copies of the HER2 gene, the HER2 protein becomes overexpressed, fueling rapid tumor growth. Approximately 20 percent of breast cancer cases are classified as HER2-positive.

Trastuzumab is a monoclonal antibody therapy that specifically targets the HER2 protein. Approved by the FDA in 1998, it binds to the extracellular domain of HER2 and prevents cancer cells from receiving growth signals. Pertuzumab is another therapy often used in combination with trastuzumab and chemotherapy. It works by inhibiting HER2 dimerization, preventing the receptor from pairing with other HER family receptors and further activating downstream signaling.

With the introduction of HER2-targeted therapies, patients with HER2-positive breast cancer experienced significantly improved survival and a reduced risk of recurrence. This discovery demonstrated that it is possible to identify and target a molecular subtype within a larger cancer category.

BRAF-Mutated Melanoma and the Challenge of Resistance

Melanoma is an aggressive form of skin cancer that arises from the uncontrolled growth of pigment-producing cells known as melanocytes. The BRAF gene normally plays a role in regulating cell growth. When mutated, however, the BRAF protein can become permanently activated, driving continuous cell division and tumor progression. Approximately 50 percent of melanomas harbor a BRAF mutation.

The most common mutation, called BRAF V600E, changes the structure of the BRAF protein in a way that keeps it permanently switched on. This constant activation sends continuous growth signals to the cell, driving tumor development.

Vemurafenib, approved by the FDA in 2011, was developed to selectively inhibit the mutated BRAF V600E kinase. Many patients experienced significant tumor shrinkage following treatment. Additional BRAF inhibitors such as dabrafenib and encorafenib were later introduced to further improve outcomes in BRAF-mutated melanoma.

NTRK Gene Fusion-Positive Tumors & Tumor-Agnostic Therapy

Neurotrophic receptor tyrosine kinase, or NTRK, genes encode tyrosine receptor kinase proteins that play an important role in normal nerve cell development. In rare cases, an NTRK gene becomes abnormally fused with an unrelated gene. These gene fusions produce abnormal proteins that are constantly switched on, sending continuous signals that cause cells to grow out of control and form tumors.

Larotrectinib, approved by the FDA in 2018, was developed as a highly selective inhibitor of TRK fusion proteins in solid tumors harboring an NTRK gene fusion. Entrectinib, approved in 2019, is another TRK inhibitor designed to target these alterations.

What makes NTRK-driven cancers interesting is that these fusions occur across multiple tumor types. Rather than targeting a specific organ site, these therapies target the underlying molecular alteration itself. This led to the emergence of tumor-agnostic therapy, where treatment selection is based on the biology of the tumor rather than its anatomical origin.

Lung Cancer & EGFR Inhibitors

Non-small cell lung cancer, or NSCLC, is the most common type of lung cancer. While smoking is a major risk factor for lung cancer overall, a subset of NSCLC tumors are driven by mutations in the epidermal growth factor receptor, or EGFR, gene. These mutations cause the EGFR protein to remain continuously activated, promoting uncontrolled cell growth and resistance to apoptosis.

Osimertinib, approved in 2015, is a tyrosine kinase inhibitor that irreversibly blocks mutant EGFR signaling. By selectively targeting this molecular driver, osimertinib can significantly reduce tumor burden, with response rates approaching 80 percent in patients whose tumors harbor activating EGFR mutations.

The development of EGFR inhibitors further reinforced that identifying and targeting specific genetic alterations can lead to meaningful clinical benefit in well-defined patient populations.

Conclusion

These examples represent only a portion of the early therapies that transformed cancer treatment. Many of these breakthroughs were built on targeting dominant driver mutations. However, not all cancers are driven by a single alteration. Tumor heterogeneity, adaptive resistance, and complex pathway interactions limit the effectiveness of mutation-only strategies. Cancer is not a static genetic disease. It is biologically dynamic.

The field of precision oncology continues to evolve. It has expanded beyond DNA mutations to explore transcriptomic signatures, proteomic profiling, the tumor microenvironment, and host immune response dynamics. These early successes validated molecular-driven therapy, reshaped cancer classification around biologically defined subtypes, and accelerated the integration of molecular diagnostics into routine clinical decision making. The future of precision oncology lies in understanding molecular networks that influence prognosis, treatment response, and recurrence risk.